用西洛斯塔治疗的患者的冠状动脉支架缩
John S Douglas1, David R Holmes, Dean J Kereiakes
1Emory University School of Medicine, Atlanta, GA, USA. john_douglas@emoryhealthcare.org
Circulation
|October 26, 2005
概括
奇洛斯塔可显著降低冠状动脉支架后的缩,改善最小的光径. 这种药物是有效的,特别是在高风险患者,而不会增加不良事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 干预心脏病学 干预心脏病学
背景情况:
- 冠状动脉支架复缩是一个重大的临床挑战.
- 支架后的极端增殖导致重新生长.
- 需要新的治疗策略来预防支架后复原.
研究的目的:
- 评价西洛斯塔在冠状动脉支架植入后减少静脉缩的疗效.
- 评估基洛斯塔对最小光径和二进制静止率的影响.
- 为了确定患者亚组,谁最受益于西洛斯塔治疗.
主要方法:
- 这是一项随机,双盲,安慰剂控制的试验,涉及705名患者.
- 患者接受阿司匹林,西洛斯塔 (100毫克两次) 或安慰剂6个月,克洛皮多格雷尔30天.
- 定量冠状动脉血管学被用来评估6个月后的静止.
主要成果:
- 奇洛斯塔治疗导致较大的最小光径 (1.77毫米对1.62毫米,P=0.01).
- 二元缩发生在22.0%的西洛斯塔患者和34.5%的安慰剂患者 (P=0.002),相对降低了36%的相对风险.
- 在糖尿病患者,患有小血管,长损伤和左前下垂动脉支架的患者中观察到显著的益处.
结论:
- 奇洛斯塔可显著降低二进制静脉复缩率,并改善支架后的光线直径.
- 该药物在高风险患者群体中表现出特别高的疗效.
- 奇洛斯塔没有增加出血,再住院,心肌梗塞或死亡率.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...


